Cantor Fitzgerald Issues Negative Estimate for PTCT Earnings

Key Points

• Cantor Fitzgerald has downgraded its FY2025 earnings estimate for PTC Therapeutics to $8.16 per share, down from $8.20, while maintaining an "Overweight" rating and a price target of $120.00.
• While Cantor Fitzgerald revised its estimates, other firms like Citigroup and Bank of America have increased their price targets for PTC Therapeutics, highlighting a range of market confidence with various ratings.
• PTC Therapeutics reported a strong quarterly earnings result, with $10.04 EPS, significantly exceeding the consensus estimate, though the company's revenue decreased 9.6% year-over-year.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for PTC Therapeutics in a report released on Tuesday, July 29th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of $8.16 per share for the year, down from their previous estimate of $8.20. Cantor Fitzgerald currently has a "Overweight" rating and a $120.00 target price on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The business's revenue was down 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.20) earnings per share.

Other equities research analysts also recently issued reports about the company. Robert W. Baird cut their target price on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Barclays upped their target price on PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a research report on Tuesday. Wall Street Zen downgraded PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. JPMorgan Chase & Co. cut their target price on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup upped their target price on PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a research report on Monday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $69.38.

PTC Therapeutics Stock Up 2.3%

PTCT traded up $1.17 during trading on Wednesday, reaching $52.11. The stock had a trading volume of 2,303,602 shares, compared to its average volume of 1,023,425. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 8.00 and a beta of 0.50. PTC Therapeutics has a 1-year low of $29.01 and a 1-year high of $58.38. The stock has a 50 day moving average of $48.95 and a two-hundred day moving average of $48.58.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 883 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the sale, the vice president directly owned 103,901 shares of the company's stock, valued at $4,781,524.02. The trade was a 0.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Pierre Gravier sold 2,516 shares of the business's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the sale, the chief financial officer directly owned 71,920 shares in the company, valued at approximately $3,557,163.20. This trade represents a 3.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,328 shares of company stock worth $254,158. Company insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

Large investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its stake in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 522 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 551 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 320 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 441 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of PTC Therapeutics in the first quarter worth $61,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.